Conferences

Canadian physicians are calling for nationwide CVD screening for all competitive high school athletes, CTV News reported this week of new guidelines issued at the Canadian Cardiovascular Congress in Toronto.

Patients with heart disease should aim to be physically active seven minutes for every 20 they’re sedentary to prolong life and prevent further cardiovascular damage, according to research presented at the 2018 Canadian Cardiovascular Congress in Toronto.

A study presented at TCT 2018 questioned the benefits of “drip-and-ship” for elderly patients with ST-segment elevation myocardial infarction (STEMI), finding patients in their 80s or older who were transferred with fibrinolytic therapy for PCI had an eight-fold risk of hemorrhagic stroke but no survival advantage.

Fewer than one-third of Chinese patients with acute coronary syndromes (ACS) receive guidance to participate in cardiac rehabilitation, according to research presented Oct. 11 at the Great Wall International Congress of Cardiology.

Lorcaserin, an appetite suppressant approved for chronic weight management in 2012, reduced overweight patients’ risk for developing type 2 diabetes (T2D) and improved remission of hyperglycemia in a study of more than 12,000 Massachusetts residents, researchers reported.

With CMS set to release a new National Coverage Determination (NCD) for transcatheter aortic valve replacement (TAVR) next June, researchers at TCT 2018 weighed in on what the new procedural volume thresholds should look like.

Some cardiologists at TCT 2018 worried negative posts about ongoing trials could affect patient enrollment, while others encouraged more colleagues to join social media discussions so the medical community can better quash misinformation.

A press conference at the 2018 Transcatheter Cardiovascular Therapeutics meeting in San Diego on Tuesday, Sept. 25, morphed into a discussion about the future of bioresorbable vascular scaffolds (BVS) and whether it’s worth pursuing bioresorbable stent technology at all.

Acute coronary syndrome patients who were given a loading dose of atorvastatin before percutaneous coronary intervention (PCI) experienced a 28 percent reduction in major adverse cardiovascular events (MACE) over the following 30 days, according to a secondary analysis of the randomized SECURE-PCI trial published in JAMA Cardiology.

With additional testing for nonobstructive coronary artery disease (CAD), researchers effectively diagnosed microvascular and/or vasospastic angina—as well as non-cardiac related chest pain—and used that information to guide therapy decisions and significantly improve angina and quality-of-life outcomes.

Intravascular ultrasound (IVUS)-guided stent implantation offers improved clinical outcomes for heart patients over a traditional angiography-guided approach, researchers from China reported at this week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Diego, California.

The Eluvia drug-eluting vascular stent system has been approved by the FDA, device maker Boston Scientific announced Sept. 24—just two days after results from the IMPERIAL trial were presented at the Transcatheter Cardiovascular Therapeutics 2018 meeting.